Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kluft

Showing results (1-10 of 291) with videos related to

Pageof 30
Sort By:
Thrombosis Research|December 25, 2010
Desirable global assaysC Kluft
Maturitas|April 6, 2004
Principles of use of surrogate markers and endpointsC Kluft
European Heart Journal|May 16, 2002
Is C-reactive protein an additional, surrogate end-point for statin treatment?C Kluft
Haemostasis|January 1, 1976
Occurrence of C1 inactivator and other proteinase inhibitors in euglobulin fractions and their influence on fibrinolytic activityC Kluft
Haemostasis|January 1, 1977
Elimination of inhibition in euglobulin fibrinolysis by use of flufenamate: involvement of C1-inactivatorC Kluft
Thrombosis and Haemostasis|April 23, 1979
Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivatorsC Kluft
Annals of the New York Academy of Sciences|December 4, 1992
In vitro diagnosis of fibrinolysis: present status and desired improvementsC Kluft
Thrombosis and Haemostasis|August 28, 2001
Hallmark discoveries on TAFI date back to 1968C Kluft
Cardiologia (Rome, Italy)|April 20, 1999
Genetic research stimulates development of individual treatmentC Kluft
Thrombosis Et Diathesis Haemorrhagica|November 15, 1975
Proceedings: C1-inactivator as a determining factor in contact activation of fibrinolysisC Kluft
Pageof 30

Showing results (1-10 of 291) with videos related to

Sort By:
Pageof 30
Thrombosis Research|December 25, 2010
Desirable global assaysC Kluft
Maturitas|April 6, 2004
Principles of use of surrogate markers and endpointsC Kluft
European Heart Journal|May 16, 2002
Is C-reactive protein an additional, surrogate end-point for statin treatment?C Kluft
Haemostasis|January 1, 1976
Occurrence of C1 inactivator and other proteinase inhibitors in euglobulin fractions and their influence on fibrinolytic activityC Kluft
Haemostasis|January 1, 1977
Elimination of inhibition in euglobulin fibrinolysis by use of flufenamate: involvement of C1-inactivatorC Kluft
Thrombosis and Haemostasis|April 23, 1979
Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivatorsC Kluft
Annals of the New York Academy of Sciences|December 4, 1992
In vitro diagnosis of fibrinolysis: present status and desired improvementsC Kluft
Thrombosis and Haemostasis|August 28, 2001
Hallmark discoveries on TAFI date back to 1968C Kluft
Cardiologia (Rome, Italy)|April 20, 1999
Genetic research stimulates development of individual treatmentC Kluft
Thrombosis Et Diathesis Haemorrhagica|November 15, 1975
Proceedings: C1-inactivator as a determining factor in contact activation of fibrinolysisC Kluft
Pageof 30